KURA
Kura Oncology, Inc.Company with tickers: KURA
CIK
1422143
CUSIP
50127T109
Shares Outstanding
88,774,365
13F Activity (30d)
181 filings
175 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $18,265,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $65,263,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-78,815,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Net Income | $-73,333,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $-0.83 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $-0.83 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |